JOP20220180A1 - مُعدلات ليباز أُحادِيُّ الجلِيسِريد - Google Patents

مُعدلات ليباز أُحادِيُّ الجلِيسِريد

Info

Publication number
JOP20220180A1
JOP20220180A1 JOP/2022/0180A JOP20220180A JOP20220180A1 JO P20220180 A1 JOP20220180 A1 JO P20220180A1 JO P20220180 A JOP20220180 A JO P20220180A JO P20220180 A1 JOP20220180 A1 JO P20220180A1
Authority
JO
Jordan
Prior art keywords
methods
disorders
modifiers
monoglyceride lipase
depression
Prior art date
Application number
JOP/2022/0180A
Other languages
Arabic (ar)
English (en)
Inventor
Michael K Ameriks
Brian Ngo Laforteza
Cynthia B Berry
Pablo Garcia-Reynaga
Jimmy T Liang
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of JOP20220180A1 publication Critical patent/JOP20220180A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JOP/2022/0180A 2020-02-10 2022-08-09 مُعدلات ليباز أُحادِيُّ الجلِيسِريد JOP20220180A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062972484P 2020-02-10 2020-02-10
PCT/EP2021/053062 WO2021160602A1 (en) 2020-02-10 2021-02-09 Monoacylglycerol lipase modulators

Publications (1)

Publication Number Publication Date
JOP20220180A1 true JOP20220180A1 (ar) 2023-01-30

Family

ID=74595268

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2022/0180A JOP20220180A1 (ar) 2020-02-10 2022-08-09 مُعدلات ليباز أُحادِيُّ الجلِيسِريد

Country Status (23)

Country Link
US (2) US11708359B2 (cg-RX-API-DMAC7.html)
EP (1) EP4103557B1 (cg-RX-API-DMAC7.html)
JP (1) JP7795466B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220140581A (cg-RX-API-DMAC7.html)
CN (1) CN115066422B (cg-RX-API-DMAC7.html)
AR (1) AR121296A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021220539A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022015116A2 (cg-RX-API-DMAC7.html)
CA (1) CA3169988A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002136A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022011275A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220376A (cg-RX-API-DMAC7.html)
DO (1) DOP2022000162A (cg-RX-API-DMAC7.html)
EC (1) ECSP22062460A (cg-RX-API-DMAC7.html)
ES (1) ES3065721T3 (cg-RX-API-DMAC7.html)
IL (1) IL295447A (cg-RX-API-DMAC7.html)
JO (1) JOP20220180A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022009804A (cg-RX-API-DMAC7.html)
PE (1) PE20221576A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552019A1 (cg-RX-API-DMAC7.html)
TW (1) TW202140465A (cg-RX-API-DMAC7.html)
UY (1) UY39066A (cg-RX-API-DMAC7.html)
WO (1) WO2021160602A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20221576A1 (es) 2020-02-10 2022-10-06 Janssen Pharmaceutica Nv Moduladores de la monoacilglicerol lipasa
KR20220158008A (ko) 2020-03-26 2022-11-29 얀센 파마슈티카 엔.브이. 모노아실글리세롤 리파아제 조절제로서의 아자스피로사이클
CA3176113A1 (en) 2020-03-26 2021-09-30 Janssen Pharmaceutica Nv Aminocyclobutanes as monoacylglycerol lipase modulators
CA3177058A1 (en) 2020-03-26 2021-09-30 Janssen Pharmaceutica Nv Aryl piperidines as monoacylglycerol lipase modulators
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
EP4384165B1 (en) 2021-08-09 2025-07-09 Janssen Pharmaceutica NV Monoacylglycerol lipase modulators for use in autism spectrum disorders
IL313987A (en) 2021-12-29 2024-08-01 Psy Therapeutics Inc Inhibiting monoacylglycerol lipase (magl)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05000945A (es) 2002-07-25 2005-05-16 Pharmacia Italia Spa Biciclo-pirazoles activos como inhibidores de la cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
EP2090576A1 (en) 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
EP2760450A1 (en) * 2011-09-30 2014-08-06 Janssen Pharmaceutica, N.V. Monoacylglycerol lipase inhibitors for the treatment of metabolic diseases and related disorders
WO2017170830A1 (ja) 2016-03-31 2017-10-05 武田薬品工業株式会社 複素環化合物
UY37174A (es) 2016-03-31 2017-10-31 Takeda Pharmaceuticals Co Un compuesto heterocíclico que tiene una acción inhibidora de monoacilglicerol lipasa
GB201613163D0 (en) * 2016-07-29 2016-09-14 Autifony Therapeutics Ltd Novel compounds
AU2018338855B2 (en) 2017-09-29 2022-04-28 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN112272670B (zh) 2019-04-16 2023-12-12 上海翰森生物医药科技有限公司 含二并环类衍生物抑制剂、其制备方法和应用
PE20221576A1 (es) 2020-02-10 2022-10-06 Janssen Pharmaceutica Nv Moduladores de la monoacilglicerol lipasa
KR20220158008A (ko) 2020-03-26 2022-11-29 얀센 파마슈티카 엔.브이. 모노아실글리세롤 리파아제 조절제로서의 아자스피로사이클
CA3176113A1 (en) 2020-03-26 2021-09-30 Janssen Pharmaceutica Nv Aminocyclobutanes as monoacylglycerol lipase modulators
CA3177058A1 (en) 2020-03-26 2021-09-30 Janssen Pharmaceutica Nv Aryl piperidines as monoacylglycerol lipase modulators

Also Published As

Publication number Publication date
ECSP22062460A (es) 2022-11-30
UY39066A (es) 2021-08-31
EP4103557C0 (en) 2026-02-18
IL295447A (en) 2022-10-01
CN115066422A (zh) 2022-09-16
KR20220140581A (ko) 2022-10-18
BR112022015116A2 (pt) 2022-09-27
US20230382902A1 (en) 2023-11-30
TW202140465A (zh) 2021-11-01
CN115066422B (zh) 2024-11-22
MX2022009804A (es) 2022-09-02
US20210253565A1 (en) 2021-08-19
PE20221576A1 (es) 2022-10-06
ES3065721T3 (en) 2026-05-07
CL2022002136A1 (es) 2023-02-03
JP7795466B2 (ja) 2026-01-07
EP4103557A1 (en) 2022-12-21
CA3169988A1 (en) 2021-08-19
AR121296A1 (es) 2022-05-04
CR20220376A (es) 2022-09-16
JP2023512729A (ja) 2023-03-28
CO2022011275A2 (es) 2022-08-30
WO2021160602A1 (en) 2021-08-19
PH12022552019A1 (en) 2023-11-29
DOP2022000162A (es) 2022-10-31
EP4103557B1 (en) 2026-02-18
US11708359B2 (en) 2023-07-25
AU2021220539A1 (en) 2022-10-06

Similar Documents

Publication Publication Date Title
SA521421575B1 (ar) مُعدلات ليباز أُحادِيُّ الجلِيسِريد
PH12022552019A1 (en) Monoacylglycerol lipase modulators
MX2022011903A (es) Azaspirociclos como moduladores de monoacilglicerol lipasa.
MX2022011901A (es) Arilo piperidinas como moduladores de monoacilglicerol lipasa.
MX2022011904A (es) Aminociclobutanos como moduladores de monoacilglicerol lipasa.
MX2023003240A (es) Moduladores de monoacilglicerol lipasa de ciclobutilamida.
EA201100461A1 (ru) Спиро-трициклические соединения как модуляторы бета-секретазы и способы их использования
MX2015011313A (es) Compuestos perfluorados de 5,6-dihidro-4h-1,3-oxazin-2-amina como inhibidores de beta-secretasa y metodos de uso.
BR112022019077A2 (pt) Moduladores da monoacilglicerol lipase
CR20220654A (es) Composiciones y métodos para modular la actividad de deshidrogenasas de cadena corta
JP2012522731A (ja) ピロロキノリンキノンのリチウム誘導体及びその製造方法
PE20210412A1 (es) Moduladores de sting (estimulador de genes de interferon) a base de ciclopentano
GEAP202416612A (en) Tricyclic urea compounds as jak2 v617f inhibitors
EP4357334A3 (en) Conjugated oligonucleotide compounds, methods of making and uses thereof
MX2024007220A (es) Psicoplastogenos de pirrolidina fusionada y sus usos.
WO2020219486A9 (en) Collagen peptide-based medicament compositions and devices and methods of production and use thereof
TN2020000160A1 (en) CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGIuR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
WO2024023262A3 (en) Nucleic acid compounds
MX2024010344A (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa
WO2024077043A3 (en) Modifying early-stage parkinson's disease progression with deep brain stimulation
MX2021009383A (es) Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico.
MX2026002937A (es) Nuevas fenilalquilaminas y su uso en el tratamiento de trastornos psiquiatricos
Hagerman et al. Case series: deep brain stimulation in patients with FXTAS
MX2024010401A (es) Quiméricos dirigido a proteólisis (protac) de proteína de translocación del linfoma del tejido linfoide asociado a las mucosas 1 (malt1)
MX2023003170A (es) Moduladores de la caseina cinasa 1 delta.